Assessing Jazz Pharmaceuticals: Insights From 7 Financial Analysts
Portfolio Pulse from Benzinga Insights
In the last three months, 7 analysts have published ratings on Jazz Pharmaceuticals (NASDAQ:JAZZ), with a mix of bullish and bearish perspectives. The average 12-month price target is now $184.86, down from $198.20. Key analysts have adjusted their ratings and price targets, reflecting dynamic market conditions and company performance. Jazz Pharmaceuticals has a market capitalization below industry benchmarks, a revenue growth rate of 1.03%, and faces challenges with profitability, ROE, ROA, and debt management.
July 02, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Jazz Pharmaceuticals has received mixed ratings from 7 analysts over the past three months, with an average 12-month price target of $184.86, down from $198.20. The company faces challenges in profitability, ROE, ROA, and debt management.
The mixed analyst ratings and lowered price targets indicate uncertainty about Jazz Pharmaceuticals' short-term performance. The company's financial challenges, including low profitability, ROE, ROA, and high debt-to-equity ratio, contribute to a neutral short-term outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100